AngioChem
Peptide drug conjugates for treating neurological diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
$4.0m | Debt | ||
| Total Funding | 000k | ||
Related Content
AngioChem is a clinical-stage biotechnology company founded in 2003 and headquartered in Montreal, Canada. The company specializes in developing pharmaceutical drugs designed to treat brain-related disorders by overcoming the blood-brain barrier (BBB). Its core technology is the Engineered Peptide Compounds (EPiC) platform, which leverages the LRP-1 mediated pathway to transport drugs across the BBB. This approach acts like a 'Trojan horse,' enabling therapeutic agents to reach the brain and treat a range of central nervous system (CNS) diseases.
AngioChem's pipeline includes small molecules and biologics targeting conditions such as brain cancer, neurodegenerative diseases, lysosomal storage diseases, and pain. A key product candidate is ANG1005, a peptide-drug conjugate of paclitaxel, which has been investigated for treating breast cancer patients with brain metastases and leptomeningeal carcinomatosis, as well as primary brain cancers like glioblastoma. Another notable development is ANG4043, a conjugate of an anti-HER2 monoclonal antibody, designed for HER2-positive intracranial tumors. The company's business model revolves around the discovery, development, and potential commercialization or partnership of these novel drug candidates that address significant unmet medical needs.
Since its founding, AngioChem has secured multiple rounds of financing. It raised $7.5 million in a Series C round in August 2018 to advance the development of ANG1005. Over its history, the company has raised a total of $13.5 million through four funding rounds involving investors such as BDC Capital and VIMAC Ventures. John Huss, a veteran with over 25 years in the pharmaceutical industry, was appointed Executive Chairman in 2016.
Keywords: blood-brain barrier, peptide drug conjugates, neurological diseases, CNS drug delivery, LRP-1 pathway, brain metastases, glioblastoma, ANG1005, paclitaxel conjugate, neuro-oncology, leptomeningeal carcinomatosis, clinical-stage biotechnology, neurodegenerative diseases, lysosomal storage diseases, engineered peptide compounds, EPiC platform, ANG4043, brain-penetrant biologics, oncology therapeutics, receptor-mediated transcytosis